{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:40:00Z","timestamp":1759412400482},"reference-count":36,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Different types of anthrax toxin neutralization assays have been utilized to measure the antibody levels elicited by anthrax vaccines in both nonclinical and clinical studies. In the present study, we sought to determine whether three commonly used toxin neutralization assays\u2014J774A.1 cell-, RAW 264.7 cell-, and CHO cell-based assays\u2014yield comparable estimates of neutralization activities for sera obtained after vaccination with anthrax vaccines composed of recombinant protective antigen (rPA). In order to compare the assays, sera were assayed alongside a common reference serum sample and the neutralization titers were expressed relative to the titer for the reference sample in each assay. Analysis of sera from rabbits immunized with multiple doses of the rPA vaccine showed that for later bleeds, the quantitative agreement between the assays was good; however, for early bleeds, some heterogeneity in relative neutralization estimates was observed. Analysis of serum samples from rabbits, nonhuman primates, and humans immunized with the rPA vaccine showed that the relative neutralization estimates obtained in the different assays agreed to various extents, depending on the species of origin of the sera examined. We identified differences in the magnitudes of the Fc receptor-mediated neutralization associated with the J774A.1 cell- and RAW 264.7 cell-based assays, which may account for some of the species dependence of the assays. The differences in the relative neutralization estimates among the assays were relatively small and were always less than 2.5-fold. However, because toxin neutralization assays will likely be used to establish the efficacies of new anthrax vaccines, our findings should be considered when assay outputs are interpreted.<\/jats:p>","DOI":"10.1128\/cvi.00513-09","type":"journal-article","created":{"date-parts":[[2010,4,8]],"date-time":"2010-04-08T02:20:49Z","timestamp":1270693249000},"page":"895-903","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":27,"title":["Comparison of Three Anthrax Toxin Neutralization Assays"],"prefix":"10.1128","volume":"17","author":[{"given":"Miriam M.","family":"Ngundi","sequence":"first","affiliation":[{"name":"Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892"},{"name":"Meade Biologics, Hillsborough, North Carolina 27278"},{"name":"University of Chicago, Chicago, Illinois 60637"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce D.","family":"Meade","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892"},{"name":"Meade Biologics, Hillsborough, North Carolina 27278"},{"name":"University of Chicago, Chicago, Illinois 60637"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsai-Lien","family":"Lin","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892"},{"name":"Meade Biologics, Hillsborough, North Carolina 27278"},{"name":"University of Chicago, Chicago, Illinois 60637"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Jen","family":"Tang","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892"},{"name":"Meade Biologics, Hillsborough, North Carolina 27278"},{"name":"University of Chicago, Chicago, Illinois 60637"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drusilla L.","family":"Burns","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892"},{"name":"Meade Biologics, Hillsborough, North Carolina 27278"},{"name":"University of Chicago, Chicago, Illinois 60637"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.it.2006.07.002","volume":"27","year":"2006","unstructured":"Baldari, C. T., F. Tonello, S. R. Paccani, and C. Montecucco. 2006. Anthrax toxins: a paradigm of bacterial immune suppression. Trends Immunol.27:434-440.","journal-title":"Trends Immunol."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00200-09"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev.cellbio.19.111301.140655","volume":"19","year":"2003","unstructured":"Collier, R. J., and J. A. Young. 2003. Anthrax toxin. Annu. Rev. Cell Dev. Biol.19:45-70.","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"747","DOI":"10.4049\/jimmunol.172.2.747","volume":"172","year":"2004","unstructured":"Dang, O., L. Navarro, K. Anderson, and M. David. 2004. Cutting edge: anthrax lethal toxin inhibits activation of IFN-regulatory factor 3 by lipopolysaccharide. J. Immunol.172:747-751.","journal-title":"J. Immunol."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1126\/science.280.5364.734","volume":"280","year":"1998","unstructured":"Duesbery, N. S., C. P. Webb, S. H. Leppla, V. M. Gordon, K. R. Klimpel, T. D. Copeland, N. G. Ahn, M. K. Oskarsson, K. Fukasawa, K. D. Paull, and G. F. Vande Woude. 1998. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science280:734-737.","journal-title":"Science"},{"key":"e_1_3_2_7_2","first-page":"37988","volume":"67","year":"2002","unstructured":"FDA. 2002. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Fed. Regist.67:37988-37998.","journal-title":"Fed. Regist."},{"key":"e_1_3_2_8_2","unstructured":"FDA. 2007. Anthrax: Bridging Correlates of Protection in Animals to Immunogenicity in Humans. Transcript of a workshop. http:\/\/www.fda.gov\/cber\/minutes\/workshop-min.htm\n."},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1016\/S0264-410X(01)00021-4","volume":"19","year":"2001","unstructured":"Fellows, P. F., M. K. Linscott, B. E. Ivins, M. L. Pitt, C. A. Rossi, P. H. Gibbs, and A. M. Friedlander. 2001. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine19:3241-3247.","journal-title":"Vaccine"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1016\/j.vaccine.2006.05.044","volume":"24","year":"2006","unstructured":"Gorse, G. J., W. Keitel, H. Keyserling, D. N. Taylor, M. Lock, K. Alves, J. Kenner, L. Deans, and M. Gurwith. 2006. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA 102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine24:5950-5959.","journal-title":"Vaccine"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.biologicals.2003.09.003","volume":"32","year":"2004","unstructured":"Hering, D., W. Thompson, J. Hewetson, S. Little, S. Norris, and J. Pace-Templeton. 2004. Validation of the anthrax lethal toxin neutralization assay. Biologicals32:17-27.","journal-title":"Biologicals"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0264-410X(98)80112-6","volume":"16","year":"1998","unstructured":"Ivins, B. E., M. L. Pitt, P. F. Fellows, J. W. Farchaus, G. E. Benner, D. M. Waag, S. F. Little, G. W. Anderson, Jr., P. H. Gibbs, and A. M. Friedlander. 1998. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine16:1141-1148.","journal-title":"Vaccine"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1073\/pnas.79.10.3162","volume":"79","year":"1982","unstructured":"Leppla, S. H. 1982. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations in eukaryotic cells. Proc. Natl. Acad. Sci. U. S. A.79:3162-3166.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2008.01.007"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1517\/14712598.7.6.843","volume":"7","year":"2007","unstructured":"Li, Y., K. Sherer, X. Cui, and P. Q. Eichacker. 2007. New insights into the pathogenesis and treatment of anthrax toxin-induced shock. Expert Opin. Biol. Ther.7:843-854.","journal-title":"Expert Opin. Biol. Ther."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.65.12.5171-5175.1997"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.vaccine.2003.07.004","volume":"22","year":"2004","unstructured":"Little, S. F., B. E. Ivins, P. F. Fellows, M. L. Pitt, S. L. Norris, and G. P. Andrews. 2004. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine22:422-430.","journal-title":"Vaccine"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/j.vaccine.2003.12.027","volume":"22","year":"2004","unstructured":"Little, S. F., W. M. Webster, B. E. Ivins, P. F. Fellows, S. L. Norris, and G. P. Andrews. 2004. Development of an in vitro-based potency assay for anthrax vaccine. Vaccine22:2843-2852.","journal-title":"Vaccine"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.mib.2003.12.001","volume":"7","year":"2004","unstructured":"Moayeri, M., and S. H. Leppla. 2004. The roles of anthrax toxin in pathogenesis. Curr. Opin. Microbiol.7:19-24.","journal-title":"Curr. Opin. Microbiol."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.6.3276-3283.2004"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00003-08"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.74.1.794-797.2006"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.68.4.617-629.2004"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1016\/S0264-410X(01)00234-1","volume":"19","year":"2001","unstructured":"Pitt, M. L., S. F. Little, B. E. Ivins, P. Fellows, J. Barth, J. Hewetson, P. Gibbs, M. Dertzbaugh, and A. M. Friedlander. 2001. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine19:4768-4773.","journal-title":"Vaccine"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1086\/423937","volume":"190","year":"2004","unstructured":"Quinn, C. P., P. M. Dull, V. Semenova, H. Li, S. Crotty, T. H. Taylor, E. Steward-Clark, K. L. Stamey, D. S. Schmidt, K. W. Stinson, A. E. Freeman, C. M. Elie, S. K. Martin, C. Greene, R. D. Aubert, J. Glidewell, B. A. Perkins, R. Ahmed, and D. S. Stephens. 2004. Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J. Infect. Dis.190:1228-1236.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3201\/eid0810.020380","volume":"8","year":"2002","unstructured":"Quinn, C. P., V. A. Semenova, C. M. Elie, S. Romero-Steiner, C. Greene, H. Li, K. Stamey, E. Steward-Clark, D. S. Schmidt, E. Mothershed, J. Pruckler, S. Schwartz, R. F. Benson, L. O. Helsel, P. F. Holder, S. E. Johnson, M. Kellum, T. Messmer, W. L. Thacker, L. Besser, B. D. Plikaytis, T. H. Taylor, Jr., A. E. Freeman, K. J. Wallace, P. Dull, J. Sejvar, E. Bruce, R. Moreno, A. Schuchat, J. R. Lingappa, S. K. Martin, J. Walls, M. Bronsdon, G. M. Carlone, M. Bajani-Ari, D. A. Ashford, D. S. Stephens, and B. A. Perkins. 2002. Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg. Infect. Dis.8:1103-1110.","journal-title":"Emerg. Infect. Dis."},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/j.1462-5822.2006.00840.x","volume":"9","year":"2007","unstructured":"Rossi Paccani, S., F. Tonello, L. Patrussi, N. Capitani, M. Simonato, C. Montecucco, and C. T. Baldari. 2007. Anthrax toxins inhibit immune cell chemotaxis by perturbing chemokine receptor signalling. Cell. Microbiol.9:924-929.","journal-title":"Cell. Microbiol."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"25990","DOI":"10.1074\/jbc.M301232200","volume":"278","year":"2003","unstructured":"Soelaiman, S., B. Q. Wei, P. Bergson, Y. S. Lee, Y. Shen, M. Mrksich, B. K. Shoichet, and W. J. Tang. 2003. Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough. J. Biol. Chem.278:25990-25997.","journal-title":"J. Biol. Chem."},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1086\/430708","volume":"41","year":"2005","unstructured":"Subramanian, G. M., P. W. Cronin, G. Poley, A. Weinstein, S. M. Stoughton, J. Zhong, Y. Ou, J. F. Zmuda, B. L. Osborn, and W. W. Freimuth. 2005. A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin. Infect. Dis.41:12-20.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1084\/jem.150.3.580","volume":"150","year":"1979","unstructured":"Unkeless, J. C. 1979. Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J. Exp. Med.150:580-596.","journal-title":"J. Exp. Med."},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/01.LAB.0000080599.43791.01","volume":"83","year":"2003","unstructured":"Vasconcelos, D., R. Barnewall, M. Babin, R. Hunt, J. Estep, C. Nielsen, R. Carnes, and J. Carney. 2003. Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis). Lab. Invest.83:1201-1209.","journal-title":"Lab. Invest."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00194-09"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00712-06"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.74.1.394-398.2006"},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1099\/00221287-147-6-1677","volume":"147","year":"2001","unstructured":"Welkos, S., S. Little, A. Friedlander, D. Fritz, and P. Fellows. 2001. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology147(Pt 6):1677-1685.","journal-title":"Microbiology"},{"key":"e_1_3_2_36_2","first-page":"982","volume":"122","year":"1998","unstructured":"Zaucha, G. M., M. L. Pitt, J. Estep, B. E. Ivins, and A. M. Friedlander. 1998. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch. Pathol. Lab. Med.122:982-992.","journal-title":"Arch. Pathol. Lab. Med."},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jim.2004.12.022","volume":"298","year":"2005","unstructured":"Zmuda, J. F., L. Zhang, T. Richards, Q. Pham, D. Zukauskas, J. L. Pierre, M. W. Laird, J. Askins, and G. H. Choi. 2005. Development of an edema factor-mediated cAMP-induction bioassay for detecting antibody-mediated neutralization of anthrax protective antigen. J. Immunol. Methods298:47-60.","journal-title":"J. Immunol. Methods"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00513-09","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00513-09","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:43:08Z","timestamp":1627591388000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00513-09"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1128\/CVI.00513-09"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00513-09","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"2009-12-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-03-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}